Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Expanded Access Program to Treat Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma With Daraxonrasib

NCT07573215 is registered in ClinicalTrials.gov with Revolution Medicines, Inc. as lead sponsor.

NCT NCT07573215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07573215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Expanded Access Program to Treat Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma With Daraxonrasib
Lead sponsor
Revolution Medicines, Inc.
Phase
Expanded access
Overall status
Approved for marketing
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
257

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreas adenocarcinoma, pancreatic adenocarcinoma, pancreatic adenocarcinoma metastatic, pancreatic adenosquamous carcinoma, pancreatic cancer, pancreatic cancer metastatic, pdac, pdac - pancreatic ductal adenocarcinoma